Internal Medicine
Lilly antibody drug fails in a Covid-19 study; others go on
28 Oct, 2020 | 09:10h | UTCLilly antibody drug fails in a Covid-19 study; others go on – CNBC
Outpatient management of COVID-19: Rapid evidence review
28 Oct, 2020 | 09:11h | UTCOutpatient Management of COVID-19: Rapid Evidence Review – American Family Physician
USPSTF draft statement now recommends starting colorectal cancer screening at 45
28 Oct, 2020 | 08:57h | UTCDraft Recommendation Statement: Colorectal Cancer Screening – U.S. Preventive Services Task Force
Commentaries: Colorectal cancer screening should start five years earlier — at 45 — expert panel says – STAT AND USPSTF Lowers Colorectal Cancer Screening Age to 45 in Draft Recommendation – NEJM Journal Watch
Meta-analysis: Most therapies for fibromyalgia are not supported by high-quality evidence
28 Oct, 2020 | 08:52h | UTCAssociation of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis – JAMA Internal Medicine (free for a limited period)
Commentary: Evidence Lacking for Most Fibromyalgia Treatments, Meta-Analysis Finds – NEJM Journal Watch
Observational Study: Ticagrelor, compared with clopidogrel, is not associated with better outcomes for patients with ACS treated with PCI
28 Oct, 2020 | 08:54h | UTCAssociation of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention – JAMA (free for a limited period)
Editorial: Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes – JAMA (free for a limited period)
Author Interview: Ticagrelor or Clopidogrel for Antiplatelet Therapy After Percutaneous Intervention for Acute Coronary Syndrome? – JAMA
Commentary on Twitter
In @JAMA_current, our article comparing ticagrelor and clopidogrel in patients with an acute coronary syndrome undergoing PCI. A remarkable international collaboration. Bottom line: more expensive med not better. https://t.co/SDAyI7Q1MV pic.twitter.com/RFmmy4qvrW
— Harlan Krumholz (@hmkyale) October 27, 2020
Systematic review: Antithrombotic drugs for people with antiphospholipid syndrome
28 Oct, 2020 | 08:50h | UTC
Preventing the spread of SARS-CoV-2 with masks and other “low-tech” interventions
27 Oct, 2020 | 09:51h | UTCPreventing the Spread of SARS-CoV-2 With Masks and Other “Low-tech” Interventions – JAMA
Commentary on Twitter
The essentiality of 😷😷 and low-tech tools even when vaccination programs are getting implemented. And call for universal masking now. https://t.co/Egyh0vjn5S by @NIAIDNews Andrea Lerner, Tony Fauci @JAMA_current pic.twitter.com/E1QeUW2bpE
— Eric Topol (@EricTopol) October 26, 2020
JACC Journal series gives in-depth look at COVID-19’s impact on the heart
27 Oct, 2020 | 09:49h | UTCNews release: Journal series gives in-depth look at COVID-19’s impact on the heart – American College of Cardiology
JACC Focus Seminar 1: Coronavirus and Cardiometabolic Syndrome
JACC Focus Seminar 2: Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes
JACC Focus Seminar 3: Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia
COVID-19 – Lessons learned and questions remaining
27 Oct, 2020 | 09:46h | UTCCOVID-19 – Lessons Learned and Questions Remaining – Clinical Infectious Diseases
Commentary on Twitter
🔥Excellent article🔥
COVID-19 – Lessons Learned and Questions Remaining@CarlosdelRio7 @davidantibiotic https://t.co/c0VG4yyJXO pic.twitter.com/7Bxn1mVttT— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) October 26, 2020
Randomized trial suggests rapid intermittent bolus of hypertonic saline is the best approach for the treatment of symptomatic hyponatremia
27 Oct, 2020 | 09:36h | UTC
For managing symptomatic #hyponatremia, both rapid intermittent bolus (RIB) and slow continuous infusion of hypertonic saline are safe and effective, but RIB achieves a target serum sodium sooner and needs lesser therapeutic re-lowering of serum sodium https://t.co/J4y4BbA855
— JAMA Internal Medicine (@JAMAInternalMed) October 26, 2020
[Preprint] Randomized trial: Nitazoxanide does not improve symptoms in mild Covid-19 disease
25 Oct, 2020 | 23:46h | UTCEarly use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial – medRxiv
Clinical Update: Virology, transmission, and pathogenesis of SARS-CoV-2
25 Oct, 2020 | 23:48h | UTCVirology, transmission, and pathogenesis of SARS-CoV-2 – The BMJ
Commentary on Twitter
https://twitter.com/bmj_latest/status/1320425173976256513
Perspective: The race to make COVID antibody therapies cheaper and more potent
25 Oct, 2020 | 23:43h | UTCThe race to make COVID antibody therapies cheaper and more potent – Nature
[Abstract Only] Randomized trial: Effect of Finerenone on chronic kidney disease outcomes in Type 2 diabetes
25 Oct, 2020 | 23:34h | UTCEffect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Finerenone Linked to Reduced Cardiorenal Events for Chronic Kidney Disease – HCPLive
Commentary on Twitter (thread – click for more)
‼️Effect of Finerenone on CKD outcomes in T2DM
⚡️Finerenone decreased risk of CKD progression by 18%
⚡️Finerenone decreased CV morbidity & mortality by 14%
Published in @NEJM today https://t.co/XvshpZZCK4@ASNKidney #Kidneywk pic.twitter.com/FOkxnG1enz
— Aisha Shaikh (@aishaikh) October 23, 2020
Perspective: COVID-19 can affect the heart
25 Oct, 2020 | 23:39h | UTCCOVID-19 can affect the heart – Science
Commentary from the author
https://twitter.com/EricTopol/status/1320427201351745536
Narrative systematic review: Benefits of medication charts provided at transitions of care
25 Oct, 2020 | 23:29h | UTC
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
25 Oct, 2020 | 23:25h | UTCOriginal guideline and commentaries: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
[Abstract only] Preliminary study suggests age-adjusted D-dimer can exclude left atrial thrombus in patients with atrial fibrillation
25 Oct, 2020 | 23:26h | UTCD-dimer blood concentrations to exclude left atrial thrombus in patients with atrial fibrillation – Heart (link to abstract – $ for full-text)
Commentary on Twitter
A nice study on the use of D-dimer for excluding left atrial thrombus.
Patients with D-dimer < (10 x patient's age) had 100% sensitivity and NPV for excluding LA thrombus.
This represented 60% of the population, who could in theory safely avoid TOE. https://t.co/OFUy9caWd0
— Mark Mills (@DrMarkMills) October 25, 2020
Down syndrome tied to 10 times the risk of COVID-19 death
23 Oct, 2020 | 09:13h | UTCDown syndrome tied to 10 times the risk of COVID-19 death – CIDRAP
Original study: COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study Of 8 Million Adults – Annals of Internal Medicine
Randomized trial: Convalescent plasma ineffective for patients hospitalized with Covid-19
23 Oct, 2020 | 09:15h | UTCEditorial: Convalescent plasma is ineffective for covid-19 – The BMJ
Commentary on Twitter
Just published @bmj_latest: A randomized trial of convalescent plasma for moderate covidhttps://t.co/dUvEMFSLHG
No benefit. It was underpowered to detect mortality reduction with 464 patients. A large RCT is needed to resolve the question, but these findings are not encouraging. pic.twitter.com/WGtz9IVSZe— Eric Topol (@EricTopol) October 23, 2020
Pro/con debate: Therapeutic anticoagulation in hospitalized patients with Covid-19 without established thromboembolism
23 Oct, 2020 | 09:12h | UTCAnticoagulation in Hospitalized Patients with Covid-19 – New England Journal of Medicine
Related editorial: Anticoagulation in COVID-19: It Is Time for High-Quality Evidence – Journal of the American College of Cardiology
Study: COVID-19 is at least 5 times deadlier than flu for hospitalized patients
23 Oct, 2020 | 09:09h | UTCCOVID-19 is at least 5 times deadlier than flu for hospitalized patients – LiveScience
Commentary on Twitter
Patients hospitalized in @VeteransHealth facilities for #COVID19 were at higher risk for serious complications and death than those hospitalized for flu, a new MMWR report finds. Learn more: https://t.co/66ry7TJon4. pic.twitter.com/rCKMsVS03b
— CDC (@CDCgov) October 20, 2020
Podcast: Deep vein thrombosis and pulmonary embolism
23 Oct, 2020 | 08:58h | UTC#238 DVT / PE Triple Distilled – The Curbsiders Internal Medicine Podcast
Guidelines for evaluation and management of pulmonary disease in Sjögren’s
23 Oct, 2020 | 08:57h | UTCConsensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s – CHEST
Best practices in managing cardiac arrest in the emergency department during the COVID-19 pandemic
22 Oct, 2020 | 09:44h | UTC